Dr. Afua Basoah is a neuroscientist turned turned healthcare communicator, turned healthcare consultant who has spent over two decades working at the intersection of public health, commercial strategy, and social impact.

‍

Angelica Conraths is the co-founder and Managing Director of fembites, a Berlin-based femtech startup developing evidence-based nutrient solutions for every phase of a woman's life. Following her own hormonal health journey, she now leads the company’s business development and go-to-market strategy, bringing women's health into mainstream retail.
‍

Her mission: to build a world where the female body is not overlooked, but fully understood – medically, economically, and socially.

Asima Ahmad, MD, MPH, FACOG, is the Co-founder and Chief Medical Officer (CMO) of Carrot Fertility, the leading global fertility, family-building, and lifelong hormonal healthcare platform providing care for everyone, everywhere. As Carrot’s CMO, Dr. Ahmad leads clinical strategy and oversees the company’s expansive network of in-person providers and virtual experts, including reproductive endocrinologists, urologists, adoption experts, mental health specialists, OB/GYNs, doulas, and midwives.

Burçak Şimşek: a Global Pharmaceuticals & Consumer Health Leader; a seasoned leader with over 20 years of experience shaping the future of the pharmaceutical and consumer health industries.

Previously, Burçak revitalized Bayer's Nutritional and Digestive Health portfolios, driven by a relentless focus on unlocking unmet needs to empower individuals in their health journeys. Her strategic vision and hands-on leadership have led to significant advancements in health outcomes. Burçak's mission is to create meaningful health impacts by championing patient-centric solutions that address the unique health journeys of women. Her work has made her a respected voice in advancing women's health and well-being in today's complex and evolving landscape.

A former England and Super League netball player, Charlotte previously held key positions at British Swimming, the Beijing 2008 and London 2012 Olympic Games and Rugby World Cup, before joining Manchester City Football Club in 2015.
As Director of Operations and Development, Charlotte oversaw the strategic direction and delivery of operations and people development programmes at Manchester City’s Boys’ Academy. Charlotte then took on the role of Interim Academy Director of the boys’ academy before moving to become Managing Director of Manchester City Women in December 2023. In her first year at the helm, she oversaw several major signings, announced the development of a £10 million bespoke training facility for the women’s first team, and saw the team return to UEFA Women’s Champions League football. During the 2024/25 season Charlotte secured ex-Swedish international Therese Sjögran as the team’s Director of Football and also announced Hannah Dingley, the first and only woman to have overseen a professional men's team in English football, as the Head of the Girls Academy.

Dr. Chen Mao Davies is the founder and CEO of Anya. Before founding Anya, Chen had a dream career in visual effects, contributing to blockbuster films such as Gravity and Blade Runner 2049, and winning both Oscar and BAFTA awards for Best Visual Effects. Her life took a transformative turn after becoming a mother and facing significant challenges with breastfeeding and early motherhood. Driven by her personal experience, Chen founded Anya to revolutionise women’s health support through innovation and empathy.

Anya is an award-winning HealthTech start-up that combines cutting-edge AI with leading healthcare expertise to deliver 24/7 support across women’s health journeys, including fertility, pregnancy, parenting, and menopause. Widely adopted by the NHS, Anya reaches over 7 million people in the UK, with 1 in 9 birthing families accessing its support through public health services. In the private sector, Anya is offered as both an employee benefit and an insurance solution, providing personalised women’s health support around the clock.

Chris Curry, MD, PhD, is Oura’s Clinical Director of Women’s Health, where she supports the Chief Medical Officer in guiding the vision for Oura’s global healthcare programs and partnerships. Her leadership supports collaboration across all parts of the company that touch women’s health, including science and research, product, and healthcare partnerships.

Dr. Curry brings experience and insight in medicine, digital health, and research. Prior to joining the Oura team, she was at Apple, where she led the product and research work on women’s health, including Cycle Tracking and Pregnancy Mode. Her scientific expertise is reflected in her leadership on the Apple Women’s Health Study.

Donna Parr, Managing Partner at CBIV, has more than 30 years of experience managing venture capital, growth equity, and private debt portfolios of up to $1 billion. She has been a manager of two biotech-related funds (GrowthWorks Canadian Fund and Canadian Medical Discoveries Fund) and has held roles at several pension funds including OMERS and CPP. She is currently on the boards of Constellation Software and Topicus.com. Donna holds a Master’s degree in International Relations from the University of Toronto and earned her MBA from the Schulich School of Business.

Dr Samana Brannigan is Head of Health Technologies at Innovate UK, the UK’s national innovation agency, where she leads the Women’s Health Strategy. With over 20 years of experience in healthcare innovation, Samana works with a dedicated team to deliver national programmes that bring targeted funding, ecosystem connections, and tailored support to UK businesses developing solutions for areas of unmet need. She leads flagship initiatives such as the Biomedical Catalyst and spearheaded Accelerating Femtech - Innovate UK’s first targeted programme for women’s health- to build momentum, support innovators, and strengthen theUK’s position as a global leader in this space. Delivered in collaboration with partners including Health Innovation Networks and the Royal College of Obstetricians and Gynaecologists (RCOG), this work reflects Innovate UK’s commitment to closing the women’s health gap, unlocking both improved health outcomes and significant economic growth opportunities for the UK.

‍

Ekaterina Gianelli is a Venture Partner at Calm/Storm, with a background as a Kauffman Fellow and Angel Investor. She has made significant investments in various startups, including Yeply, Elsa, and NØIE, and has held leadership roles at companies like Inventure and Klevu. With a diverse portfolio of investments in companies like DrugStars and Yogaia, Ekaterina Gianelli's career highlights include her role as a Venture Partner at Calm/Storm and her involvement as a Kauffman Fellow, showcasing her expertise in venture capital and startup ecosystem.

A former top-level athlete, R&D engineer, and graduate of the ESCP Business School MBA (Paris, France) in healthcare industry management, Emeline Hahn co-founded Fizimed in 2017 with three associates. As CEO, she leads Fizimed’s strategic, commercial, and communication efforts, building a pioneering FemTech company that improves women’s health worldwide and empowers them to reclaim control of their bodies through innovative medical devices. Fizimed’s flagship products include Emy Trainer, a connected pelvic floor rehabilitation probe that helps thousands of women combat urinary incontinence and is reimbursed in Germany, and Emy Pump, a portable, hands-free breast pump that allows mothers to continue breastfeeding with freedom and flexibility. Recognized as one of the “40 Forbes Women” of 2023 who have made a global impact, Emeline is shaping the future of women’s health through innovation and purpose.

Head of Healthcare for Barclays Business Banking leading a team of 50 specialist healthcare managers all around the country supporting healthcare clients to grow their businesses. Emma has a strong medical background being  a qualified Veterinary Surgeon in addition to many years working across the bank in financing roles having previously been a Director in the Private Equity Debt Structuring team.

‍

Esther is the Founding Managing Partner of THENA Capital, a UK based MedTech venture capital fund focused on digital healthcare solutions and medical devices, with over 10 years of experience in growth strategy consulting and venture capital. Esther has an MBA from the University of Oxford and for over 10 years, has been a trusted advisor to large brands across consumer sectors and in particular within healthcare, advising them on consumer growth strategies and how best to adapt their commercial models to changing environments and trends.

Gina King is a Partner at Supernode Global, a venture capital firm backing early-stage companies that transform modern life across wellbeing and productivity. With 25 years of global experience spanning Wall Street, startups, and emerging tech, Gina brings a unique cross-cultural lens and operator mindset to investing in technology that elevates the human experience.

Before entering venture capital, Gina spent over a decade at Jefferies, where she held roles in investment banking and corporate marketing. She then founded two startups: Domaine Somm, a platform delivering access to curated culinary & wine selections and experiences, and Kinemai, an AI-powered digital health app for human mobility.

A graduate of U.C. Berkeley, Gina also holds executive certifications from Stanford GSB and the Culinary Institute of America. She serves on multiple boards and champions greater representation in startups and venture capital, with a focus on women and underrepresented founders.

Hana is an Investment Director at Big Issue Invest, where she co-leads the Growth Impact Fund in partnership with Unltd. With over 15 years of experience in banking and management consulting, she specializes in corporate strategy, data, and technology transformation. brings global impact investing expertise, having launched a venture philanthropy firm in collaboration with the Qatari Foundation and worked with an Impact Tech VC in Silicon Valley. Her focus spans across sectors including Health & Social Care, FemTech, FinTech, AgriTech, and Foundational AI. In addition, Hana has hands-on experience advising and mentoring underrepresented founders, providing support in fundraising, go-to-market strategies, hyper-growth, hiring, and board development.

Hannah Samano, Forbes 30 Under 30, is the Founder & CEO of Unfabled, the UK’s fastest-growing platform for women’s health and wellness. A former tech and innovation lead at Unilever and founding employee at Kasha (now Africa’s leading healthtech), Hannah is on a mission to close the gender health gap. Unfabled combines a curated consumer platform for women's wellbeing with its own bestselling supplement range, now stocked nationwide in Boots. Through Unfabled Labs, the company also powers B2B insights to advance women’s health.

Heather Jackson is CEO and Co-Founder of GenM - the Menopause Partner for Brands and Home of the MTick, the universal shopping symbol for menopause-friendly products. She is a visionary leader and her personal journey through perimenopause exposed the lack of education, support and product availability, was the catalyst to co-found GenM. The mission is to unite responsible brands and retailers, normalise the menopause conversation, and deliver much-needed choice, trust, and visibility to the menopausal market. Ultimately, empowering women to shop with confidence for products to improve the lived experience of menopause.

Dr O’Neill is CEO and Founder of Hertility, an award-winning women’s health company shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. Hertility provides end-to-end gynaecology care from testing to treatment. Dr Helen O’Neill is also an Associate Professor in Reproductive and Molecular Genetics at the Institute for Women’s Health, University College London. She has an MSc in Prenatal Genetics and Fetal Medicine, a PhD in Stem Cell Biology and Developmental Genetics from UCL and has spent the last 17 years researching genetics, fertility and women’s health.

Ira Guha is the founder of Asan, an award-winning menstrual health venture working to end period poverty globally. As a graduate student at Harvard, Ira designed and patented the Asan menstrual cup — named the UK's best reusable period cup by The Evening Standard for two years in a row. Asan has enabled over 100,000 underserved women and girls around the world to safely attend school and work during periods, and has averted over 200 million plastic pads from landfills. In 2025, Asan was named a Top 100 UK Startup by startups.co.uk as well as a Top 100 UK Social Enterprise by Natwest. For her work at Asan, Ira has been awarded the Cartier Women’s Initiative Fellowship, the Mulago Rainer-Arnhold Fellowship, and the Innovate UK Unlocking Potential Award.

Janice Sanon is a Senior Innovation & Growth Specialist working at Innovate UK Business Growth with extensive experience supporting startups and scale-ups. She has previously worked on accelerator programs, helping over 100 companies secure funding, develop intellectual property strategies, and scale internationally. Her strategic guidance has enabled businesses to raise over £2M in funding and expand into five countries. Specialising in public funding, Janice frequently delivers masterclasses on grant funding best practices. Her key sectors include health and sustainability, where she is passionate about empowering impact-driven innovators to achieve their goals. In addition to her advisory work, she is a femtech advocate.

Jenny Saft is the General Manager of Global Markets at Progyny. She co-founded and served as CEO of Apryl, a platform designed to help employers provide inclusive fertility benefits for their employees, which was later acquired by Progyny. Before founding Apryl, Jenny held roles in project management and business development at leading companies such as Adyen and Fyber.

Kate Ferguson is Chief of Staff at Samphire Neuroscience, where she leads on strategy, operations, and marketing initiatives for neurotechnology in women’s health. She has overseen projects ranging from NHS clinical trials of Nettle™, the company’s CE-certified wearable for menstrual pain and mood symptoms, to U.S. market expansion with the company's second neurotechnology product, Lutea™ - with a focus on navigating regulatory frameworks and making science both accessible and impactful.

Kate started her career at J.P. Morgan, before moving into the health sector as a consultant supporting a variety of early-stage start-ups on fundraising, clinical trial design, and health economics. She holds an MPhil in Bioscience Enterprise from the University of Cambridge and a BSc in Bioprocessing of New Medicines from UCL.

‍

Dr Kendall Jamieson Gilmore is lead strategy advisor in the System Strategy Unit at the Department of Health and Social Care, focussed on innovation, life sciences, and data and digital priorities in the 10-year health plan. He is also Associate Director of Strategy at The National Institute for Health and Care Excellence (NICE), where he leads policy and strategy projects and NICE's enhanced horizon scanning function. Before joining NICE Kendall was based in Italy where he completed an EU fellowship in healthcare performance intelligence. He has worked for 14 years in healthcare policy, strategy and transformation with experience at a social investment company, at NHS England, and in the Department of Health and Social Care.

Lina Chan is the Director of Women’s Health at Holland and Barrett. Previously she was the CEO and co-founder of Parla.  Lina spent most of her career working as a private equity investor in the US and the UK.  After experiencing multiple pregnancy losses, difficulty conceiving and preterm birth, Lina became acutely aware of the gaps in women’s health care. She founded Parla in 2018 with the mission to improve women’s access to expert support and health education.  She quickly grew the company to serve thousands of women before being acquired by Holland & Barrett, Europe’s largest health and wellness retailer, in 2022.  Lina believes that women's health care should address the physical as well as mental health needs across a women's reproductive life-span. She is passionate about women’s health and entrepreneurship leading her to support a wave of new women in the space.  Lina is also a regular public speaker advocating for women’s health issues. Born in Brazil, Lina lives in London with her husband and 3 children.

Luana is an investment associate at Supernode Global, an early-stage, London-based fund, focused on technologies that meaningfully enhance our personal and professional lives. With a career spanning founder, operator and investor roles, she has co-founded a design-tech startup, scaled operations as Chief of Staff for venture-backed startups, and worked at data-powered VCInReach Ventures. At Supernode, she backs early-stage consumer and B2B companies across two themes: Wellness (Health & Vitality, Life Optimisation, Community & Social) and Productivity(Intelligent Workflows, Creative Enablement, Professional Augmentation). The firm’s Fund II already includes health tech companies, including one tackling women’s hormonal health.

As head of Software and AI regulation, I work to enhance patient safety by driving innovation while eliminating harmful, fraudulent and substandard products from the market. With a background in medicine and data science, I have seen first hand how bias impedes patient care and am committed to ensuring that products entering the NHS do not inflict patients with the same discrimination that doctors historically have.

Mathieu Horras is a medtech entrepreneur and the CEO and co-founder of ASPIVIX SA, a Swiss-based company revolutionizing gynecological care with innovative, patient-centric solutions. With over 15 years of experience in the medical device industry, he has held leadership roles across R&D, marketing, and business development in both large corporations and startups. An engineer by training (ParisTech) with an MBA from INSEAD and Wharton, Mathieu has successfully raised over USD 15 million to fund the development, clinical validation, and international launch of Carevix®, a modern alternative to the tenaculum.

Mindy is Co-Director at the NHS Innovation Accelerator. She is responsible for the programme’s execution while providing guidance to innovators. Her journey began in 2013 when she joined UCLPartners, eventually transitioning to the NIA in 2017.
She has spent much of her extensive career working in the health and life sciences sector, holding senior leadership and operational roles across health and higher education institutions.

With more than 25 years of experience, Miranda Cole has extensive experience helping clients navigate increasing regulatory scrutiny from governments and competition authorities. She also supports clients in aligning their competition strategies and policy engagement in response to new regulatory frameworks.

Miranda helps a broad range of companies with transactional and behavioural matters, advising on merger control; foreign direct investment and foreign subsidies reviews of mergers, acquisitions, and other transactions.

Rhiannon is a highly empathetic product leader with deep experience building world-class software products, and the world-class product teams that underpin those products. At Clue, she serves as its CEO, responsible for leading the company as it creates a medical-grade reproductive health app that can empower people with cycles from their first period to their last with personalized, data-driven health insights. Prior to her role as CEO, Rhiannon was the company’s Chief Product Officer for nearly three years. Rhiannon has experience across a range of industries and business models, including companies like Shazam, Vend, BBC and more. She has held product leadership roles in London, Silicon Valley, Auckland and Berlin, giving her a global perspective on customer needs. She is the proud parent of three completely wild and wonderful children.

Rob has spent over 30 years financing, developing, manufacturing, and launching medical device and digital health technologies, alongside executing successful exits. Most recently he was CEO at viO HealthTech before the acquisition by Ultrahuman in the summer of 2025. Ultrahuman has a range of health and wellness devices, and the acquisition enabled the launch of a new joint product on the day of the acquisition: Cycle and Ovulation Pro, incorporates algorithms originally developed for viO's OvuSense product developed over 15 years and trained on a dataset of over 260,000 cycles. Now heading up Ultrahuman's Women's Health and Longevity division, Rob continues to help support the inception and growth of startup companies in the medical and digital health fields.
‍
His sector experience spans in-vitro diagnostic laboratory and point of care testing; cardiology; obstetrics; gynaecology; fertility; general women’s health; EMG, EEG and sleep neurology; dentistry, and ophthalmology.

‍

Ruth Brännvall is the founder of Impact Invest Scandinavia (Stockholm/London). Over the past two decades, her organisation has run several entrepreneurship programmes for women and supported different types of investors in structuring and managing impact investments. With large gaps persisting in funding towards better health, she decided to set up the first Nordic venture fund to provide patient, flexible capital.

Ruth is also the author of several scientific publications about the scaling of innovations in underserved markets, and financing of early stage ventures.

PhD from the Royal Institute of Technology (KTH) in Stockholm, Exec MBA from Warwick Business School. www.impactinvest.se

‍

Dr. Sarah Montgomery-Taylor leads initiatives to improve health information quality at Google for Health, developing strategies to surface reliable content and reduce misinformation. A critical part of this mission is her work as the clinical lead for generative AI evaluation, where she oversees the quality and safety assessment of Google's AI models and products for health applications before they launch.
Sarah joined Google over seven years ago, initially working on clinical and product strategy for DeepMind's healthcare portfolio before her team transitioned to the broader Google for Health team. Prior to her work in the technology sector, she was a practicing pediatrician and was actively involved in academic health services research.

Dr. Soum Rakshit, FIET, FRSA is the Co-Founder & CEO of MV.Health. He did his PhD in Biomedical Engineering and created a startup in eye recognition which was acquired by a US defence company. He then spent 7 years in management consulting on large technology projects. In 2014, Soum started MV.Health to bring defence electronics and medical expertise together to create medical devices that adapt to the user's body & deliver targeted vibrations to address major issues like pelvic pain, period pain, erectile dysfunction, prostatitis and more.

Dr Tahreema Matin is a UK-based medical leader and board-certified radiologist with a DPhil from Oxford, working at the intersection of digital health, innovation, and regulation. She holds national roles at NHS England and Prenuvo, and serves as a Clinical Safety Officer, Trustee at Picker, and Policy Expert at the Institution of Engineering and Technology. A former Principal Investigator and journal editor, she is passionate about advancing safe, ethical, and equitable adoption of AI and diagnostics to transform personalised and preventive care for women.

Tatum Getty is the founding General Partner of THENA Capital, a UK MedTech VC fund supporting UK startups in creating transformative health experiences through commercialising and scaling beyond the UK, whilst using a Gender-Smart Investing strategy. Fund I is focussed on early-stage digital healthcare solutions and fast-tracked medical devices, backing businesses addressing key need spaces across care delivery, patient support, and medical product verticals covering chronic conditions, women's health, cancers, mental health, and beyond. Prior to starting the fund with her two partners, Tatum was a startup marketing operator in the health and wellness sector at SoulCycle and Barry's Bootcamp, and consulted for the launches of wellness brands like Tonal, Hermosa Protein, and The Assembly.

Tola Sunmonu-Balogun is an Associate Partner at McKinsey & Company, specialising in public health with a distinctive focus on women’s health. She leads McKinsey’s healthcare work in Nigeria and has deep expertise in health systems strengthening in low- and middle-income countries.

Tola works across the public, private, and philanthropic sectors to design and implement service delivery models that expand access to primary healthcare for underserved women and communities. She has led initiatives to revitalise primary health facilities, develop national health workforce strategies, scale community health worker programs, and design sustainable approaches to reduce maternal mortality. She has also convened high-profile women’s health gatherings in Africa, bringing together leaders from government, philanthropy, media, and industry to build momentum for greater investment in women’s health.

Beyond health, Tola has supported organisations in telecommunications, retail banking, and fintech, where she has led major transformations that delivered significant operational improvements and year-on-year growth. She is also deeply committed to developing the next generation of African leaders at McKinsey, mentoring colleagues across levels, and championing inclusion with a particular focus on women.

Tola holds an MBA from the Wharton School of the University of Pennsylvania and a BSc in Economics (with honours) from Stanford University.

‍

Tom Bohills is an experienced technology lawyer specialising in helping startups navigate the complex, fast-moving world of highly regulated sectors like fintech, healthtech, and AI. He qualified at White & Case before leading legal functions at two multi-award-winning UK fintechs, giving him a unique perspective from both private practice and in-house.

In 2019, he founded Founders Law to disrupt the traditional legal model and make top-tier legal support more accessible to early-stage and scaling companies. Today, Founders Law provides agile, embedded legal services across all sectors—covering everything from IP and contracts to data privacy, fundraising, and international expansion. Tom is particularly passionate about guiding founders through the legal “grey areas” that often arise in dynamic, regulated industries, helping them scale with confidence and speed.

Triin is the Founder & CEO of Sie Ventures, backing early stage companies with diverse founding teams across UK and Europe. Formerly she was Vice President at The Venture Collective, investing in companies across US and UK. She was also an early-stage investor at Founders Factory and Startupbootcamp. Before her career in investments, she was a founder and operator in three companies across FinTech and Future of Work.

Valentina Milanova is the founder and CEO of Daye, a gynae health research and development company seeking to close the gender health gap with proprietary medical and diagnostic devices aimed at common, yet under-served gynae health conditions, ranging from period and pelvic pain to cervical cancer prevention. Valentina's research has been published in The Journal of Endometriosis and Uterine Disorders as well as BMC Women's Health and The Journal of Clinical Microbiology. In 2022 and 2023 Valentina was featured on Forbes 30 Under 30, and in 2024 The Daye Diagnostic Tampon was named as Invention of the Year by TIME Magazine.

Daye is the leading women's health platform addressing the most prevalent, yet often overlooked health conditions, from period and pelvic pain to cervical cancer prevention.

Valerie Evans is a seasoned investor at Five Seasons Ventures, a pan-European fund focused on category defining consumer brands across the food, beauty, health, home, and wellness spaces. She has experience in advising Fortune 500 companies focused on beauty and consumer and created the women's health thesis in her previous investment role at consumer growth fund, The Craftory. While she invests in all verticals of consumer at FSV, she continues to lead on health and wellness, and in particular, women's health.She sits on the board of Artah, a supplements company focused on metabolic health, and Puresport, a sports nutrition brand focused on clean recovery and performance support. While she has American roots, she has lived in London and now Paris.

Vandana Subramanian is a Visiting Partner with Antler UK, where she helps shape the firm’s healthcare and life sciences strategy. She is also building a UK/Europe - anchored seed/series A fund focused on healthcare AI, women’s health, and precision diagnostics. A London Business School Sloan Fellow and member of its Private Capital Committee, she actively shapes the UK university ecosystem with venture and growth capital. A 2x founder with an Accel Partners - backed exit, Vandana has built multi-milliondollar businesses across India, Europe, and the US in oncology, women’s health, clinical informatics, genomics, therapeutics, imaging, and AI. She has raised over US$140M from pre-seed to series D and was named among the Top 50 Women in Tech in the UK by McKinsey.

‍

Wendy Powell is the founder and CEO of MUTU System, the clinically proven and medically recommended digital health solution for pelvic health and core strength. Backed by NHS contracts, clinical trials, and global medical referrals, Wendy leads the charge in delivering real, evidence-based answers to women at every life stage, from puberty or pregnancy to postpartum, perimenopause, and beyond.

Xisca is passionate about the life sciences industry and women’s health. She is a lawyer who specialises in regulatory law in the biopharmaceutical and medical technologies sectors, both in the UK and at EU level.

Xisca advises life sciences companies on a broad range of regulatory law topics including: regulatory strategies for bringing products (that be medicines, medical devices, or in vitro diagnostics) to market, product life cycle management and clinical studies. She also advises on AI as medical devices.

Before joining the London-based law firm Bristows, she was an in-house regulatory lawyer at Pfizer, where she provided regulatory law support to all business units and functions at EU and global level, gaining excellent knowledge of the pharmaceutical industry enabling her to bring a strong business approach to her legal advice.

Zeynep Bagwell is a technology consultant with deep expertise in personal care and women’s health innovation. She leads the Personal Care sector at 42 Technology, supporting global brands and fast-growth companies through end-to-end product development, spanning early concept development, technical feasibility, scale-up, and manufacturing. Zeynep is known for translating complex technical challenges into commercially viable solutions. Her work often sits at the interface of consumer products and medical technology, where regulatory, design, and user requirements must align.